Haichuang Pharmaceutical (688302. SH) is an international innovative pharmaceutical enterprise based on targeted protein degradation (TPD) (including PROTAC technology, molecular gel degradation technology, etc.), deuterated drug research and development, and translational medicine technology platforms, aiming to develop Best in class and First in class drugs with significant clinical needs. The company focuses on the research and development of innovative drugs in major therapeutic fields such as cancer, metabolic diseases, and self motivation, with a focus on providing effective, safe, and affordable drugs for patients. It is committed to developing and producing innovative drugs with global rights.